Although the mechanism involved in the anti-tumor properties of the tankyrase inhibitor (AZ1366) in this study appears not to implicate the WNT/β-catenin signaling pathway, it is intriguing that alternative tankyrase mechanisms may be responsible for overcoming irinotecan therapy resistance in a subset of CRC tumors. Here, TNKS is linked to neoplasm.